QHM-2025-6465 Maryport Group Practice - Local Enhanced Service

The procurement process, initiated by the NHS North East and North Cumbria Integrated Care Board, is for the provision of a local enhanced service titled QHM-2025-6465 Maryport Group Practice - Local Enhanced Service, falling under the health services industry category. The procurement, located in the UKC region, specifically in Maryport, involves near patient testing (high risk) drug monitoring services. The process culminates in an award, with the contract running from 1st April 2025 to 31st March 2026, although services are being provided on an implied contract basis prior to April 2025.

The procurement method is a Direct Award Process A under the Health Care Services (Provider Selection Regime) regulations 2023, which is outside the scope of the 2023 Procurement Act and 2024 Procurement Regulations. This contract presents substantial growth opportunities for businesses proficient in delivering health-related services, specifically those capable of offering specialised drug monitoring solutions. Companies aligning with the profile of existing service providers, such as large-scale health service entities, could find this award advantageous.

The limited procurement method, focused on awarding without prior publication, signifies that businesses already recognised as trusted providers may have a competitive edge. The award criteria are based on the lack of a viable alternative provider, emphasizing the need for exceptional quality and cost performance in the services offered.